BioNTech SE

AI Score

XX

Unlock

100.75
5.37 (5.63%)
At close: Mar 24, 2025, 3:59 PM
100.50
-0.25%
After-hours: Mar 24, 2025, 07:59 PM EDT
5.63%
Bid 98
Market Cap 24.18B
Revenue (ttm) 2.73B
Net Income (ttm) -673.02M
EPS (ttm) -3.02
PE Ratio (ttm) -33.36
Forward PE -36.66
Analyst Buy
Ask 100.61
Volume 863,952
Avg. Volume (20D) 765,239
Open 95.65
Previous Close 95.38
Day's Range 95.65 - 100.98
52-Week Range 76.53 - 131.49
Beta 0.31

About BNTX

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for tripl...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 10, 2019
Employees 6,772
Stock Exchange NASDAQ
Ticker Symbol BNTX
Full Company Profile

Analyst Forecast

According to 16 analyst ratings, the average rating for BNTX stock is "Buy." The 12-month stock price forecast is $144, which is an increase of 42.92% from the latest price.

Stock Forecasts
2 weeks ago
-6.61%
BioNTech shares are trading lower. Morgan Stanley ... Unlock content with Pro Subscription
2 weeks ago
-3.15%
BioNTech SE shares are trading lower. The company reported Q4 financial results.